Approach to Patients with Oligoprogression using stereotactic radiotherapy

Programme description

This program focuses on the management of patients with oligoprogression, a condition where limited progression of cancer occurs in a small number of sites despite systemic treatment. It explores the role of stereotactic radiotherapy (SRT) as a highly precise treatment option aimed at controlling localized disease progression while maintaining the benefits of systemic therapies.

Key areas of focus include:

• Defining oligoprogression and its clinical significance
• Mechanisms and principles of stereotactic radiotherapy
• Selecting appropriate candidates for SRT in the context of oligoprogression
• Integrating SRT with ongoing systemic treatment approaches (e.g., immunotherapy, targeted therapies)
• Clinical evidence supporting the use of SRT for oligoprogression
• Managing treatment-related side effects and patient outcomes
• Case-based discussions and treatment planning

This program is designed for oncologists, radiologists, and medical professionals involved in the treatment of cancer patients, providing advanced insights into the integration of stereotactic radiotherapy with modern systemic therapies to improve patient care and outcomes.